Differences in prescribed medicinal cannabis use by cannabinoid product composition: Findings from the cannabis as medicine survey 2020 (CAMS-20) Australia-wide study.

Benjamin T Trevitt Sasha BaileyLlewellyn MillsThomas R ArkellAnastasia SuraevIain S McGregorNicholas Lintzeris

Published in: PloS one (2024)

This Australia-wide study found clear differences in consumer-reported experiences of prescribed THC- and CBD-containing products. Current prescriptions of these products do not always align with relevant clinical guidance. Educating prescribers around cannabinoid products is essential to ensure optimal prescribing practices and to prevent avoidable drug side effects and interactions.

Keyphrases

primary care
healthcare
emergency department
cross sectional
adverse drug
social media